

Index

- Action Program on Essential Drugs, 18,20,141-142
Adverse reactions section of label, 5,43-44
Advertising, pharmaceutical
 codes of conduct and, 131-139
 detail men, 111
 in developing countries, 110-112
 fairness and balance test, 95
 medical journals, 111-112
 over-the-counter drugs, 11, 95-96
 prescription drugs, 11,95-96
 reminder advertisements, 18, 137
 WHO ethical criteria, 16-17, 133-135
Alcohol as an ingredient, 41
AMA. See American Medical Association
AMA Drug Evaluations, 32, 106
American Hospital Formulary Service, 106
American Law Institute, 13, 118
American Medical Association, 32, 106
Anabolic steroid study, 156-157
Antibiotics: The Wrong Drugs for Diarrhoea, 151
Antidepressant drugs, 152
Antidiarrhea drugs, 151-152, 155-156
Antitrust laws, 120-121
APED. See Action program on Essential Drugs
Argentina, drug advertising, 111
Association of the British Pharmaceutical Industry,
 146

*Bad Medicine: The Prescription Drug Industry in the
 Third World*, 42
Balasubramaniam, K., 150
Batch certificates, 19, 145
Bitter Facts About Drugs, 151

Boycotts, 13, 117, 123, 131
Brazil
 drug advertising, 111
 drug labeling, 164
 drug registration, 163-164
 obtaining product labels, 28-29
 package inserts, 29
 sample product selection, 28
 selection for study, 27
Breast-Milk Substitutes Code. See International Code
 of Marketing of Breast-Milk Substitutes
Bristol-Myers Squibb Co., 115
BUKO, 152
Bush, George, economic sanctions against Iraq, 122

Cancer treatment, off-label prescribing and, 105-106
Carter, Jimmy, freezing of Iranian assets, 122
Certificates for pharmaceutical products, 19
Certification Scheme on the Quality of
 Pharmaceutical Products Moving in
 International Commerce, 19,20, 142-146
Chetley, Andrew, 151
Chloramphenicol study, 155
CIOMS. See Council for International Organizations
 of Medical Sciences
Clayton Act, 120
Cleared for Export, 151
Clinical pharmacology section of label, 4,40
Clioquinol study, 155-156
Code of Conduct for Companies Operating in South
 Africa, 15
Code of Conduct for Translational Corporations, 15-
 16,23,24, 128, 130-131

188 I Drug Labeling in Developing Countries

- Code of Pharmaceutical Marketing Practices, 9, 17-18
 - criticisms of, 138-139
 - description, 135-136
 - implementation, 136-137
 - reporting and resolution of violations, 137-138
- Codes of conduct, 15-18, 23-24
 - under international law, 128-135
- Collaborating Center for Monitoring of Adverse Drug Reactions, 20
- Collaborating Centre for International Drug Monitoring, 146-147
- Combination drugs, 103-104
- Comity principle of international law, 118-119
- Consumer Action and Resource Kit on Pharmaceuticals*, 149
- Consumer Alerts*, 150
- Consumer groups
 - health advocates, 149-153
 - IFPMA ethical criteria and, 134-135
 - infant formula and, 132
 - international programs and, 21
- Consumer Interpol, 149-150
- Contraindications section of label, 5, 4243
- Council for International Organizations of Medical Sciences, 24, 135

- Data Sheet Compendium*, 146
- DEACs. See Drug Export Act countries
- Description section of label, 4, 40
- DESI. See Drug Efficacy Study Implementation
- Detail men, 111
- Dictionaire Vidal*, 146
- Dingell, John, 2
- DMP. See Drug Management and Policies Division, World Health Organization
- Dosage and administrative section of label, 5-6, 44
- Drug Diplomacy: Decoding the Conduct of a Multinational Pharmaceutical Company*, 151
- Drug Disinformation: What British and Multinational Drug Companies Tell Doctors About Their Products, At Home and Abroad*, 152
- Drug Efficacy Study Implementation, 95
 - new drug review, 103-104
- Drug Export Act countries, 45, 49
- Drug **Export** Act of 1986, 2, 6-7, 45, 96-98
- Drug Facts and Comparisons*, 32

- Drug Information for the Health Care Professional*, 32, 106
- Drug Labeling studies, 155-162
- Drug Management and Policies Division, World Health Organization, 18-19, 142, 146
- The Drugging of the Americas*, 158, 159, 161
- Drugs and Primary Health Care*, 151
- Drugs and World Health*, 152
- Drugs Used in Anesthesia*, 146
- Drugs Used in Mycobacterial Diseases*, 146
- Drugs Used in Parasitic Diseases*, 146

- EAA. See Export Administration Act
- Economic sanctions, 121-123
- Effects principle of international law, 13, 14, 117-118, 125
- Enforcement Report*, 148
- The Essential Drugs Monitor*, 18, 142
- “Ethical and Scientific Criteria for Pharmaceutical Advertising,” 16, 133
- “Ethical Criteria for Medicinal Drug Promotion,” 16-17, 18, 24, 133-135
- European Community, codes of conduct, 15
- Expert Advisory Panel on Drug Evaluation, 7, 49
- Expert Review Group
 - first review, 31-32
 - medical importance standard, 30
 - original label examination, 29
 - scoring review, 36
- Export Administration Act, 13, 121-123
- Exported drugs
 - FDCA and, 11
 - labeling, 11, 96-98
 - tropical disease drugs, 12, 98
 - unapproved drugs, 11, 96
- Extraterritorial jurisdiction
 - antitrust laws, 120-121
 - health and safety of foreign nationals and, 14-15, 125-126
 - international law principles, 12-13, 117-119, 125-126
 - U.S. laws allowing, 13-14

- Fairness and balance test, 95
- FCPA. See Foreign Corrupt Practices Act
- FDA. See Food and Drug Administration
- FDA Consumer Information*, 148
- FDA Medical Bulletin*, 148

- FDCA. See Food, Drug, and Cosmetic Act
- Federal Congress of Development Action Groups.
See BUKO
- Federal Register*, 148
- Federal Trade Commission, 23
- Federal Trade Commission Act, 120
- Food, Drug, and Cosmetic Act, 9,91
export of pharmaceuticals, 11
1962 amendments, 95
- Food and Drug Administration
cooperation with WHO programs, 148
exported pharmaceuticals labeling, 11
extraterritorial jurisdiction, 12-15
FDCA and, 91
international activities, 20, 143, 147-148
labeling standard, 3
tropical disease drug export, 12
unapproved drug export, 11
unlabeled indications, 104
U.S. drug labeling, 9-11
- Foreign Corrupt Practices Act, 13-14,22-23, 123-125, 126
- Foreign relations law, 118-120
- France
drug approval process, 107
drug efficacy standards, 107
- GAIT. See General Agreement on Tariffs and Trade
- General Accounting Office
export of unapproved drugs, 96
off-label prescribing study, 105
- General Agreement on Tariffs and Trade, 15
- Germany
drug approval process, 107
labeling, 107
- Global Marketing of Pharmaceuticals: Prescription for Disaster*, 150
- “Good Practices in the Manufacture and Quality Control of Drugs,” 142
- Guidelines for Multinational Corporations, 15, 128
- “Guiding Principles for Small National Authorities,” 20, 148
- HAI. See Health Action International
- HAI News*, 151
- “The Hartog and Schulte-Sasse Study,” 152, 161
- Harvard Medical School, 153
- Health Action International
code of conduct, 150-151
description, 21, 149, 150
ethical criteria critique, 151
IFPMA critique, 151
Health Horizons, 137
- Hoechst, 152
- House Subcommittee on Health and the Environment
of the Committee on Energy and Commerce, 98
- IBFAN. See International Baby Food Action Network
- IEEPA. See International Emergency Economic Powers Act
- IFM, See International Association of Infant Food Manufacturers
- IFPMA. See International Federation of Pharmaceutical Manufacturers Associations
- ILO. See International Labour Office
- India
multinational corporations and, 116
WHO collaborating center, 146
- Indications section of label, 4-5,41-42
- Indonesia, multinational corporations and, 116
- IND. See Investigational new drug exemption
- Inert ingredients, 41
- Infant formula, 16,23-24, 125, 131-133
- Ingredients section of label, 4,4041
- INRUD. See International Network for the Rational Use of Drugs
- INRUD News*, 153
- Institutional Review Boards, 100
- Insult or Injury? An Enquiry into the Marketing and Advertising of British Food and Drug Products in the Third World*, 151
- Interfaith Center on Corporate Responsibility, 131
- International Affairs Staff, Food and Drug Administration, 147
- International Association of Infant Food Manufacturers, 16, 132
- International Baby Food Action Network 131, 132
- International Chamber of Commerce, 15, 128
- International Code of Marketing of Breast-Milk Substitutes, 16,23-24, 128
description, 131-132
implementation, 132-133
- International Conference of Drug Regulatory Authorities, 20

190 I Drug Labeling in Developing Countries

- International Emergency Economic Powers Act, 13, 122-123
- International Federation of Pharmaceutical Manufacturers Associations
codes of conduct, 16, 17-18, 24, 128, 133, 135-139
drug advertising, 111
product promotion guidelines, 9
- International Labour Office, 15, 128
- International law
codes of conduct, 15-18, 128-135
foreign relations law, 118-120
multinational corporations, 116-120
principles, 12-13, 117-119, 125-126
rule of reasonableness and, 119
- International Network for the Rational Use of Drugs, 21, 148, 153
- International Non-proprietary Name, 136
- International Organization of Consumers Unions, 21, 132, 149-150
labeling studies, 155-162
- International Pharmaceutical Federation, 49
- International programs for labeling improvement
consumer groups, 21, 149-153
FDA international activities, 20, 143, 147-148
prescribing information distribution, 7, 18-19, 49, 146
safety and efficacy information access, 19-20
USAID programs, 20-21, 145-146, 148-149
WHO Certification Scheme, 19, 20, 142-146
- “International Regulation of the Supply and Use of Pharmaceuticals,” 152
- International Union of pharmacology, 49
- International Workshop on Consumer Health and Drug Information and Education, 149
- Investigational new drug exemptions
application, 99-100
exemption for clinical trials in human beings, 96
- IOCU. See International Organization of Consumers Unions
- IRBs. See Institutional Review Boards
- Italy, bribery of officials, 124
- Japan
bribery of officials, 123-124
inert ingredients database, 41
- Journal of the American Medical Association*, 106
- Kennedy, Edward, 2
- Kenya
drug registration and labeling, 164-165
obtaining product labels, 29
package inserts, 29
sample product selection, 28
selection for study, 27
- Labeling changes, prescription drugs, 94
- Laws. See *specific laws and regulations by name*;
U.S. drug labeling laws and regulations
- Lee. See Silverman, Lydecker, and Lee, labeling studies
- Lockheed Corp., 123-124
- Lydecker. See Silverman, Lydecker, and Lee, labeling studies
- MaLAM. See Medical Lobby for Appropriate Marketing
- Management Sciences for Health, 153
- Manual for Rural Health Workers: Diagnosis and Treatment with Essential Drugs*, 18, 142
- Marketing. See Advertising
- Medawar, Charles, 152
- Medical Bulletin*, 20, 147
- Medical Devices and Radiological Health*, 148
- Medical importance standard, 3, 30-31, 32, 35, 40, 49, 104
- Medical Lobby for Appropriate Marketing, 21, 137-139, 152-153
- Medicines Control Agency, 107
- Merck & Co., 115
- MNCs. See Multinational corporations
- Model Guide to Good Prescribing*, 18, 142
- “Model List of Essential Drugs,” 7, 49, 142, 161
- Model Prescribing Information*, 142
- Moscow Olympics boycott, 123
- Multinational corporations
bribery of foreign officials, 13-14, 123-125, 126
codes of conduct and, 15, 114, 128-139
description, 113-114
drug advertising, 111
drug labeling influences, 8
extraterritorial jurisdiction and, 120-126
growth of, 114-115
health and safety of foreign nationals, 14-15, 125-126
host country laws, 106

- international law, 116-120
 - joint venture arrangements, 115
 - labeling studies, 155-162
 - legal control, 8-9
 - markets, 7-8
 - proprietary products licensing to foreign companies, 116
 - structure, 8, 115-116
 - trade embargoes and economic sanctions, 121-123
 - U.N. standards for, 9, 130-131
- NAS. See National Academy of Sciences
- National Academy of Sciences, new drug review, 103-104
- Nationality principle of international law, 12, 13, 117, 125-126
- NDA. See New Drug Application
- Nestle Corp., 131-133
- Nestle Infant Formula Audit Commission, 132
- New Drug Applications, 91,99, 101-102
- over-the-counter drugs, 95
- New drug approval
- clinical trials, 100-101
 - definition of "new," 98-99
 - Investigational New Drug exemption, 99-100
 - NDA review, 101-102
 - preclinical research, 99
- Nigeria, labeling study, 160-161
- OECD. See Organization for Economic Co-operation and Development
- Off-label prescribing, 104-106
- Office of International Affairs, U.S. Public Health Service, 147
- One Drug at a Time: A Report on the Limitation of Fixed Ratio Combination Drugs*, 152
- Options for Congressional action, 21-24
- Organization for Economic Co-operation and Development, 14, 15, 124-125, 128
- Osifo, Nosakhare Guy, 160-161
- OTA Labeling evaluation process
- analysis and final results, 37
 - company response evaluation, 32-34
 - Expert Review Group reviews, 31-32,36
 - interim and revised overall scores, 37
 - medical importance standard, 30-31, 32, 35, 40-49
 - preliminary screening, 31
 - provision of scoring sheets to companies, 34-36
 - queries to companies, 32
 - scoring* of labels, 34-36,4049
 - summary sheets for additional responses, 36-37
- OTC. See Over-the-counter drugs
- Over-the-counter drugs
- advertising, 11,95-96
 - classes, 95
 - labeling, 10-11,94-95
 - package inserts, 29
- Overdosage section of label, 6,44
- Package inserts, 10,29-30,92-93, 107
- in developing countries, 109-110
- Package labels for prescription drugs, 92-93
- PAHO. See Pan American Health Organization
- Pan American Health Organization, 147, 148
- Panama
- drug registration and labeling, 165-166
 - obtaining product labels, 28-29
 - package inserts, 29
 - prescribing guides, 3
 - sample product selection, 28
 - selection for study, 27
- PDR. See *Physicians' Desk Reference*
- Peddling Placebos: An Analysis of Cough and Cold Remedies*, 151
- Pediatric drug prescribing, 105-106
- Pfizer, Inc., 115
- Pharma-Brief*, 152
- Pharmaceutical labeling studies, 155-162
- Pharmaceutical Manufacturers Association, 7,28,45, 135
- Physicians' Desk Reference*, 31, 146
- Physicians' Desk Reference for Nonprescription Drugs*, 31
- Pills, Profits and Politics*, 158
- PMA. See Pharmaceutical Manufacturers Association
- Policies and Strategies on Drug Pricing Regulations: International Experiences*, 150
- Policy Options in Pharmaceutical Patents for Developing Asian Countries*, 150
- Post-marketing surveillance, 102-103
- Power and Dependence*, 152
- Precautions section of label, 5,43
- Prescribing guides, 3, 30
- in developing countries, 110
- Prescription drugs
- advertising, 11,95-96

192 | Drug Labeling in Developing Countries

- labeling changes, 94
- labels, 10,92-93
- package inserts, 29,92-93
- standards of evidence, 94
- Prescription for Death: The Drugging of the Third World*, 159, 162
- Problem Drugs*, 151
- Product documents, 107-108
- Promoting Health or Pushing Drugs? A Critical Examination of Marketing of Pharmaceuticals*, 151
- Protective principle of international law, 117
- The Provision and Use of Drugs in Developing Countries*, 151

- Qualitative results of OTA survey, 3940,54-91
- Quantitative results of OTA survey
 - company analysis, 6,44
 - country analysis, 6,44-54
 - labeling category analysis, 40-44
 - other industrialized country comparison, 6-7,45-49
 - overall analysis, 40
 - WHO model prescribing information, 7,49
- Queries to companies, 32-34
- A Question of Control*, 151

- The Rational Use of Drugs: A Universal Concept*, 150
- Reagan, Ronald, Breast-Milk Substitutes code and, 133
- Reminder advertisements, 18, 137
- Reporting requirements, new drugs, 102-103
- Restatement (Third) of the Law: The Foreign Relations Law of the United States*, 13-15,118
- Rhodesia, economic sanctions against, 123
- Rule of reasonableness, 119

- Sample selection, OTA Survey
 - company identification, 28
 - country selection, 27-28
 - label translations, 30
 - sample products, 28-30
- Schulte-Sasse. See "The Hartog and Schulte-Sasse Study"
- SCRIP World Pharmaceutical News*, 137
- Searle Pharmaceuticals, 151-152
 - export of unapproved drugs, 96
 - Sherman Act, 120-121
 - Silverman, Lydecker, and Lee, labeling studies, 42, 158-160
 - Social Audit, 151-152
 - labeling studies, 157-158
 - Statements of licensing status, 19, 145
 - Survey, OTA
 - category of information analysis, 4-6
 - company analysis, 6,44
 - country analysis, 6,4445
 - labeling evaluation process, 30-37
 - other industrialized country comparison, 6-7,45-49
 - process, 2-3,27-37
 - qualitative results, 39-40,54-91
 - quantitative results, 40-54
 - results, 3-7
 - sample selection, 27-30
 - scoring categories, 3-6, 34
 - WHO model prescribing information and, 7,49
 - Syntex Corp., 116

 - Ten Year Report on the IFPMA Code*, 137
 - Territorial principle of international law, 12-13, 117
 - Thailand
 - drug registration and labeling, 166-167
 - obtaining product labels, 29
 - package insets, 29-30
 - sample product selection, 28
 - selection for study, 28
 - Third International Conference of Drug Regulatory Authorities, 143
 - Trade embargoes, 13, 117, 121-123
 - Translation of foreign language labeling, 30
 - Translational Code. See Code of Conduct for Transnational Corporations
 - Treaties, codes of conduct and, 129
 - Tropical disease drugs, 98
 - export, 12

 - U.N. Centre on Transnational Corporations, 130-131
 - labeling studies, 160
 - U.N. Conference on Trade and Development Code of Conduct on Restrictive Business Practices, 15, 128
 - U.N. Council for Trade and Development, 133
 - Unapproved drugs, 96-98
 - export, 11,96-98

- United Kingdom
 drug approval process, 107
 sales representatives, 111
- United Nations. See *also specific divisions by name*
 codes of conduct, 15-16, 23, 24, 128, 130-131
 standards for MNCs, 9
- United Nations International Court of Justice, 116
- United Nations Participation Act, 123
- United States Pharmacopeial Convention, 106
- U.S. Agency for International Development, 19
 cooperative agreement with U.S. Pharmacopoeia,
 20-21, 148-149
 WHO and, 20, 145-146, 148
- U.S. Department of State, 147-148
- U.S. drug labeling laws and regulations. See *also specific laws and regulations by name*
 DESI review, 103-104
 exported drugs, 96-98
 new drug approval, 98-102
 off-label prescribing, 104-106
 over-the-counter drugs, 94-96
 post-marketing surveillance, 102-103
 prescription drugs, 92-94
- U.S. Pharmacopoeia, 148-149
 agreement with USAID, 20-21
- U.S. Public Health Service, 147
- U.S. Securities and Exchange Commission, 123
- U.S. Senate Committee on Labor and Human Resources, 105
- U.S. Trade Representative, 147
- USAID. See U.S. Agency for International Development
- USP DI. See Drug Information for the Health Care Professional*
- Veterinary Medicine, 148*
- Warnings section of label, 5,43
- Waxman, Henry, 2
- WHO. See World Health Organization
WHO Drug Information, 20, 146
WHO Model Prescribing Information, 18-19, 146
WHO Pharmaceutical Newsletter, 20, 146
- World Federation of Proprietary Medicine Manufacturers, 49
- World Health Assembly, 135, 143
- World Health Organization
 Action Program on Essential Drugs, 18,20, 141-142
 Certification Scheme, 19,20, 142-146
 codes of conduct, 16, 128
 collaborating centers, 20, 146-147
 Division of Drug Management and Policies, 18-19, 142, 146
 drug advertising, 111
 ethical criteria for drug promotion, 16-17, 24
 Expert Advisory Panel on Drug Evaluation, 7,49
 FDA and, 20
 infant formula hearings, 125
 prescribing information, 7, 18-19,49, 146
The Wrong Kind of Medicine?, 152
- Yudkin, J. S., 157

U . S . GOVERNMENT PRINTING OFFICE : 1993 0 330-065 QL 3

